louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00818142: Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder
Official title: Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eating Disorder
Type 1 Diabetes
Lead sponsor: HealthPartners Institute
Sponsor class: OTHER
Collaborators: name: International Diabetes Center at Park Nicollet
name: Park Nicollet Eating Disorder Institute
name: Park Nicollet Foundation
First posted: 2009-01-07
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals diagnosed with type 1 diabetes and an eating disorder who manipulate their insulin will be considered to join the ED/DM Recovery Group.

Brief summary: We propose to conduct a monthly group of persons with type 1 diabetes who also withhold insulin. Subjects will be asked to complete a 2-page survey (check-in sheet) at the beginning of each session and a 5-page survey (Diabetes and Eating Disorders Survey) on their first session and at their last session of their group.


Eligibility criteria: Inclusion Criteria:

* Have an eating disorder
* Have type 1 diabetes
* Withhold their insulin
* 18 years or older
* Actively being treated at EDI
* Committed to at least one appointment each month with each member of their individual EDI team (RD, CDE or RN, CDE; LP; and MD)
* Approval of participation by EDI/DM team (RD; RN; LP; MD)
* Able to attend 66% of group sessions

Exclusion Criteria:

* Psychologically not ready for this group therapy
* Have additional eating disorder issues that would make attendance in this group inappropriate
* Not committed to continuing treatment at PN's EDI
* Not being actively treated at PN's EDI
* Has type 2 diabetes

Primary outcomes:
measure: Adherence to insulin regimen.
timeFrame: Monthly
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Park Nicollet Eating Disorder Institute
state: Minnesota
Study officials:
affiliation: International Diabetes Center at Park Nicollet
name: Margaret Powers, PhD, RD, CDE
role: PRINCIPAL_INVESTIGATOR
References:
citation: Colton P, Olmsted M, Daneman D, Rydall A, Rodin G. Disturbed eating behavior and eating disorders in preteen and early teenage girls with type 1 diabetes: a case-controlled study. Diabetes Care. 2004 Jul;27(7):1654-9. doi: 10.2337/diacare.27.7.1654.
citation: Goebel-Fabbri AE, Fikkan J, Connell A, Vangsness L, Anderson BJ. Identification and treatment of eating disorders in women with type 1 diabetes mellitus. Treat Endocrinol. 2002;1(3):155-62. doi: 10.2165/00024677-200201030-00003.
Clinical trial NCT00377442: A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.
Official title: A Randomized, Open-label Crossover Study to Investigate the Potential Interaction Between GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes Mellitus Type 2
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2006-09-18
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study will assess the potential pharmacokinetic interaction between GK Activator (2) and simvastatin, and the potential effect of simvastatin on the glucose-lowering effect of GK Activator (2) in patients with type 2 diabetes. Patients will be randomized to one of 6 treatment sequences to receive single doses of a)GK Activator (2) 100mg po, b)simvastatin 80mg po and c)GK Activator (2) 100mg + simvastatin 80mg po. Dosing will take place on study days 1, 8 and 15, and there will be a 7-14 day follow-up period after the last dose. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria: Inclusion Criteria:

* adult patients aged 18-75 years;
* type 2 diabetes mellitus;
* untreated, or taken off anti-diabetic or statin therapy \>=2 weeks before study start.

Exclusion Criteria:

* type 1 diabetes mellitus, or latent autoimmune diabetes in adults;
* diabetic neuropathy, retinopathy or nephropathy;
* patients treated with insulin or PPAR gamma agonist within 6 weeks of screening.

Primary outcomes:
measure: AUC0-inf of GK Activator (2) and simvastatin acid.
timeFrame: Days 1, 8 and 15
measure: AUC0-6h of plasma glucose from pre-dose to 6h post-dose.
timeFrame: Days 1, 8 and 15
Secondary outcomes:
measure: AUC0-6h of GK Activator (2) and simvastatin acid
timeFrame: Days 1, 8 and 15
measure: AUC0-inf of M4 and simvastatin; CL/F, Cmax, tmax, t1/2.
timeFrame: Days 1, 8 and 15
measure: Cmin, tmin, Cmax, tmax, plasma glucose.
timeFrame: Days 1, 8 and 15
measure: AEs, laboratory parameters.
timeFrame: Throughout study
Other outcomes:
Locations:
city: San Antonio
country: United States
state: Texas
city: Tacoma
country: United States
state: Washington
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00571142: Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
Official title: Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Diffuse Diabetic Macular Edema
Keywords: edema
retinal thickness
diabetic retinopathy
Lead sponsor: Asociación para Evitar la Ceguera en México
Sponsor class: OTHER
First posted: 2007-12-11
Enrollment: 20
Sex: ALL
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.


Eligibility criteria: Inclusion Criteria:

* Older than 25 yo
* Diffuse diabetic macular edema with or without previous treatment

Exclusion Criteria:

* Another retinal disease
* Pregnancy

Primary outcomes:
measure: Retinal thickness
timeFrame: 3 months
Secondary outcomes:
measure: Visual acuity
timeFrame: 3 months
Other outcomes:
Locations:
city: Mexico
country: Mexico
facility: Asociacion para Evitar la Ceguera en Mexico I.A.P.
Study officials:
affiliation: Asociación para Evitar la Ceguera en México
name: Veronica Kon-Jara, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03776942: Synovial Chondrosarcoma: a Single Institution Experience
Official title: Synovial Chondrosarcoma: a Single Institution Experience
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Synovial Chondrosarcoma
Lead sponsor: Istituto Ortopedico Rizzoli
Sponsor class: OTHER
First posted: 2018-12-17
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male and Female ≥ 18 years with diagnosis of synovial chondrosarcoma with histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis

Brief summary: single institution cases series review of histological, radiological and clinical data

Detailed description: single institution cases series review of histological, radiological and clinical data. Investigators will retrieve from the archives of the Rizzoli institute all the cases with a histological diagnosis of synovial chondrosarcoma.

Eligibility criteria: Inclusion Criteria:

* Male and female patients treated at Rizzoli Institute from 01 January 1982 to 31 December 2017
* Diagnosis of synovial chondrosarcoma
* Age ≥ 18 years
* Histological slides / formalin-fixed paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the histology analysis
* Written informed consent prior to any study-specific analysis and/or data collection

Exclusion Criteria:

* Patients with histological diagnosis different from synovial chondrosarcoma

Primary outcomes:
measure: selection and review of cases of Synovial Chondrosarcoma
timeFrame: baseline (Day0)
Secondary outcomes:
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCC Rizzoli Orthopedic Institute
Study officials:
References:
citation: Ng VY, Louie P, Punt S, Conrad EU. Malignant Transformation of Synovial Chondromatosis: A Systematic Review. Open Orthop J. 2017 May 31;11:517-524. doi: 10.2174/1874325001711010517. eCollection 2017.
citation: Biazzo A, Confalonieri N. Synovial chondrosarcoma. Ann Transl Med. 2016 Aug;4(15):280. doi: 10.21037/atm.2016.06.23.
citation: Zamora EE, Mansor A, Vanel D, Errani C, Mercuri M, Picci P, Alberghini M. Synovial chondrosarcoma: report of two cases and literature review. Eur J Radiol. 2009 Oct;72(1):38-43. doi: 10.1016/j.ejrad.2009.05.029. Epub 2009 Jun 11.
citation: Campanacci DA, Matera D, Franchi A, Capanna R. Synovial chondrosarcoma of the hip: report of two cases and literature review. Chir Organi Mov. 2008 Dec;92(3):139-44. doi: 10.1007/s12306-008-0062-3. Epub 2008 Dec 4.
citation: Bertoni F, Unni KK, Beabout JW, Sim FH. Chondrosarcomas of the synovium. Cancer. 1991 Jan 1;67(1):155-62. doi: 10.1002/1097-0142(19910101)67:13.0.co;2-w.
Clinical trial NCT00456742: Efficacy of Treatment for Generalized Anxiety Disorder
Official title: Efficacy of Treatment for Generalized Anxiety Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Generalized Anxiety Disorder
Keywords: Generalized Anxiety Disorder
Anxiety
Treatment efficacy
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2007-04-05
Enrollment: 250
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants in the study will be recruited from individuals receiving treatment for generalized anxiety disorder (GAD) at the Anxiety Disorders Clinic of UBC Hospital

Brief summary: The purpose of these questionnaires is to give us an overview of how GAD has affected your life, and perhaps also to give us some clues about things that may have set you up to experience GAD.

Detailed description: For us to evaluate the efficacy of our treatment programs, we are interested in your responses before and after treatment. We use two methods to evaluate the efficacy of our treatments: questionnaires and interviews with a member of the Anxiety Disorders Clinic. As part of standard clinic procedure, each person in the program completes an in-person interview with a staff member who will determine your suitability for treatment. If you have received this questionnaire packet, it is likely that your concerns will be appropriately addressed in the Anxiety Disorders Clinic. The purpose of the questionnaire packet is to assess the severity of your generalized anxiety disorder; its impact on your functioning, and factors that may contribute to the onset or maintenance of your GAD (e.g., depression, intolerance of uncertainty). We will ask you to complete this questionnaire again when you have completed your treatment along with a brief telephone interview with a staff member of the Anxiety Disorders Clinic.

Eligibility criteria: Inclusion Criteria:

* Patients referred to the Anxiety Disorders Clinic who receive a primary diagnosis of Generalized Anxiety Disorder, and are accepted for treatment at the clinic.

Exclusion Criteria:

* Individuals who either have not sought treatment for anxiety at the Anxiety Disorders Clinic or patients who did not receive a primary diagnosis of Generalized Anxiety Disorder.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Anxiety Disorders Clinic, University of British Columbia
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Maureen Whittal, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01226342: Transcutaneous Electrical Muscle Stimulation In Chronic Obstructive Pulmonary Disease (COPD)
Official title: Transcutaneous Electrical Muscle Stimulation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Chronic obstructive pulmonary disease
Lead sponsor: The University Clinic of Pulmonary and Allergic Diseases Golnik
Sponsor class: OTHER
First posted: 2010-10-22
Enrollment: 19
Sex: ALL
Minimum age (years): 35
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Transcutaneous electrical muscle stimulation (TCEMS) is well established intervention for rehabilitation of clinically stable patients with chronic obstructive pulmonary disease.

The investigators have conceived this study to test whether TCEMS is feasible and tolerated by patients experiencing severe physical and psychical challenge of acutely exacerbated COPD.


Eligibility criteria: Inclusion Criteria:

* chronic obstructive pulmonary disease GOLD stage III or IV
* acute exacerbation of the disease

Exclusion Criteria:

* contraindications for transcutaneous electrical muscle stimulation

Primary outcomes:
measure: Scores on the feasibility scale
timeFrame: 10 days (avarage time from admission to discharge)
Secondary outcomes:
measure: Scores on the patient satisfaction scale
timeFrame: 10 days (avarage time from admission to discharge)
measure: Number of patients with adverse events as a measure of Safety and tolerability
timeFrame: 10 days (avarage time from admission to discharge)
measure: Health related quality of life on the St. George respiratory questionnaire
timeFrame: 10 days (avarage time from admission to discharge)
measure: Dyspnea on the MRC dyspnea scale
timeFrame: 10 days (avarage time from admission to discharge)
measure: Patient symptom scores on the Functional assessment of chronic illness therapy questionaire
timeFrame: 10 days (avarage time from admission to discharge)
Other outcomes:
Locations:
city: Golnik
country: Slovenia
facility: University Clinic Golnik
Study officials:
affiliation: University Clinic Golnik
name: Mitja Lainscak, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: contraindications for TCEMS
name: Mitja Kosnik, MD, PhD
role: STUDY_CHAIR
References:
citation: Meglic U, Sorli J, Kosnik M, Lainscak M. Feasibility of transcutaneous electrical muscle stimulation in acute exacerbation of COPD. Wien Klin Wochenschr. 2011 Jun;123(11-12):384-7. doi: 10.1007/s00508-011-1587-2. Epub 2011 May 25.
Clinical trial NCT00000342: Risperidone for the Treatment of Cocaine Dependence - 7
Official title: Risperidone for the Treatment of Cocaine Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Keywords: cocaine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate clinical safety and pharmacological efficacy in the treatment of cocaine dependence, to evaluate impact of treatment on craving, and to correlate evidence of baseline neurotoxic damage of cocaine with treatment outcome and clinical side-effects.


Eligibility criteria: Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Friends Research Institute
state: California
Study officials:
affiliation: Friends Research Institute, Inc.
name: Walter Ling, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05388942: Virtual Reality Hypnosis Versus Inhaled Nitrous Oxide in Anterior Shoulder Dislocation Reduction: an Open Multicenter Randomized Controlled Trial
Official title: Virtual Reality Hypnosis Versus Inhaled Nitrous Oxide to Reduce Anterior Shoulder Dislocations: an Open Multicenter Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Shoulder Dislocation
Keywords: shoulder dislocation
virtual reality
hypnosis
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2022-05-24
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Anterior shoulder dislocation (ASD) is a common situation in the emergency department (ED). Quick reductions lead to reduced mid and long term complications. No technique is superior to one another. Inhaled nitrous oxide can deal with pain reduction and anxiety but its efficacy is not optimal, with safety issues. Virtual reality hypnosis (VRH), by distracting patients from their pain, may lead to a better muscular relaxation and an easier ASD reduction.

Our first objective is to evaluate the clinical interest of VHR compared to nitrous oxide, in ASD reduction. Our second objective is to evaluate the safety of VRH in ASD reduction.

Patients over 18 years presenting an ASD \< 24 hours, will be illegible for enrollment in an open multicenter randomized controlled trial, conducted in the Great East Region in France.


Eligibility criteria: Inclusion Criteria:

* patients of 18 years and older
* consulting the ED for a ASD \< 24 hours
* with or without history of ASD
* with social insurance

Exclusion Criteria:

* non anterior shoulder dislocation
* shoulder or facial fracture or multiple trauma patient
* dementia, psychosis
* uncontrolled epilepsy
* visual or hearing issues
* claustrophobia
* vascular or nervous lesion of the dislocated arm
* contraindication with the use of inhaled nitrous oxide

Primary outcomes:
measure: Reduction of ASD procedure time
timeFrame: Day 0
Secondary outcomes:
measure: Achievement of the reduction of ASD procedure
timeFrame: Day 0
measure: Per-procedure pain
timeFrame: Day 0
measure: Passage time in the ED
timeFrame: Day 0
measure: Patient satisfaction
timeFrame: Day 0
measure: Adverse events when using HRV
timeFrame: Day 0
measure: Adverse events when using inhaled NO
timeFrame: Day 0
Other outcomes:
Locations:
city: Reims
country: France
facility: Damien JOLLY
Study officials:
References:
Clinical trial NCT02518542: Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) for Achalasia
Official title: Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) as Additional Endoscopic Treatment Options for Achalasia and Other Esophageal Motility Disorders
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Esophageal Achalasia
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2015-08-10
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Achalasia is an esophageal motility disorder, which leads to clinical symptoms such as dysphagia, regurgitation, chest pain and consecutive weight loss.

Although conventional treatment such as laparoscopic Heller myotomy (LHM) and balloon dilatation (BD) can provide sufficient symptom relief in many patients, both interventions have their individual drawbacks. Additionally, treatment after failed LHM or BD can be challenging and in few might even lead to esophagectomy.

Per oral endoscopic myotomy (POEM) and prolonged dilatation (PRD) are two novel endoscopically performed therapeutic options for achalasia and other esophageal motility disorders. Both not only appear to provide good results, when performed as initial treatment but also might be an excellent option after e.g failed LHM.

The purpose of this study is to evaluate the long-term efficacy of four different treatment options, such as POEM, PRD with stent-fixation, PD and conventional LHM for achalasia in an individualized treatment setting.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of achalsia, hypertensive lower esophageal sphincter, nutcracker esophagus, or diffuse esophageal spasm

Exclusion Criteria:

* Contraindication for EGD

Primary outcomes:
measure: Achalasia specific symptoms according to the Eckardt score (0-12)
timeFrame: 6 mo post-op
Secondary outcomes:
measure: Barium column height (cm) in esophagogram
timeFrame: 6 mo post-op
measure: Resting pressure (mmHg) at the lower esophageal sphincter
timeFrame: 6 mo post-op
measure: Stent migration
timeFrame: p.o. day 1
measure: Percent of time (min)/24h that the pH is less than 4.0 in pH-metry
timeFrame: 6 mo post-op
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Surgery, Medical University of Vienna
Study officials:
References:
Clinical trial NCT04436042: MyHand 2: An Active Hand Orthosis for Stroke Patients
Official title: MyHand 2: An Active Hand Orthosis for Stroke Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke
Hemiparesis
Keywords: Stroke
Rehabilitation
Hemiparesis
Robotics
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2020-06-17
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study is designed to further develop and test the hardware and software components of the MyHand device based on user feedback and results from our pilot study. The goal is to refine the device so that is more effective and easier for stroke patients to use to increase their hand function.

Detailed description: From previous experimentation with the MyHand device, the investigators have determined that the device can improve the grasping ability of stroke patients. The investigators now aim to make the controls more intuitive and accurate for the users, to enable subjects to grasp a wider array of objects, to make the donning and doffing of the device easier, and to continue to assess the MyHand as it helps subjects in functional tasks.

Eligibility criteria: Inclusion Criteria:

* Adults over 18 years old
* History of stroke(s) with most recent stroke at least six months ago
* Upper extremity weakness with impaired ability to complete daily activities with affected hand
* Full passive range of motion in all digits
* Intact cognition to follow directions
* Gross control of proximal upper extremity musculature

Exclusion Criteria:

* Other neurological conditions besides stroke
* Other orthopedic conditions to affected upper extremity
* Significant spasticity in affected upper extremity that impairs device fit

Primary outcomes:
measure: Device Usability and Utility Questionnaire Score
timeFrame: Up to 1 year at study completion
Secondary outcomes:
Other outcomes:
Locations:
city: New York City
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Joel Stein
role: PRINCIPAL_INVESTIGATOR
References: